{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:26:17Z","timestamp":1707524777093},"reference-count":38,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,16]]},"DOI":"10.7759\/cureus.30348","type":"journal-article","created":{"date-parts":[[2022,10,16]],"date-time":"2022-10-16T10:56:47Z","timestamp":1665917807000},"source":"Crossref","is-referenced-by-count":0,"title":["Iron Deficiency in Heart Failure: What Do We Know So Far?"],"prefix":"10.7759","author":[{"given":"Amr","family":"Elkammash","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rasha M","family":"Farahat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aya","family":"Al Sattouf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julius","family":"Lenaerts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khin Yadanar","family":"Maung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aayesha","family":"Khatri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2016.248","article-title":"Targeting iron metabolism in drug discovery and delivery","volume":"16","author":"Crielaard BJ","year":"2017","unstructured":"Crielaard BJ, Lammers T, Rivella S. Targeting iron metabolism in drug discovery and delivery. Nat Rev Drug Discov. 2017, 16:400-23. 10.1038\/nrd.2016.248","journal-title":"Nat Rev Drug Discov"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00412.2005","article-title":"Iron imports. IV. Hepcidin and regulation of body iron metabolism","volume":"290","author":"Ganz T","year":"2006","unstructured":"Ganz T, Nemeth E. Iron imports. IV. Hepcidin and regulation of body iron metabolism. Am J Physiol Gastrointest Liver Physiol. 2006, 290:G199-203. 10.1152\/ajpgi.00412.2005","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.physiol.69.031905.164337","article-title":"Iron homeostasis","volume":"69","author":"Andrews NC","year":"2007","unstructured":"Andrews NC, Schmidt PJ. Iron homeostasis. Annu Rev Physiol. 2007, 69:69-85. 10.1146\/annurev.physiol.69.031905.164337","journal-title":"Annu Rev Physiol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/nrm1620","article-title":"Iron-sulphur cluster biogenesis and mitochondrial iron homeostasis","volume":"6","author":"Rouault TA","year":"2005","unstructured":"Rouault TA, Tong WH. Iron-sulphur cluster biogenesis and mitochondrial iron homeostasis. Nat Rev Mol Cell Biol. 2005, 6:345-51. 10.1038\/nrm1620","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2018.07.015","article-title":"Iron deficiency in heart failure: an overview","volume":"7","author":"von Haehling S","year":"2019","unstructured":"von Haehling S, Ebner N, Evertz R, Ponikowski P, Anker SD. Iron deficiency in heart failure: an overview. JACC Heart Fail. 2019, 7:36-46. 10.1016\/j.jchf.2018.07.015","journal-title":"JACC Heart Fail"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24820","article-title":"Iron deficiency across chronic inflammatory conditions: international expert opinion on definition, diagnosis, and management","volume":"92","author":"Cappellini MD","year":"2017","unstructured":"Cappellini MD, Comin-Colet J, de Francisco A, et al.. Iron deficiency across chronic inflammatory conditions: international expert opinion on definition, diagnosis, and management. Am J Hematol. 2017, 92:1068-78. 10.1002\/ajh.24820","journal-title":"Am J Hematol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-286260","article-title":"Detection, evaluation, and management of iron-restricted erythropoiesis","volume":"116","author":"Goodnough LT","year":"2010","unstructured":"Goodnough LT, Nemeth E, Ganz T. Detection, evaluation, and management of iron-restricted erythropoiesis. Blood. 2010, 116:4754-61. 10.1182\/blood-2010-05-286260","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.022853","article-title":"Myocardial iron deficiency and mitochondrial dysfunction in advanced heart failure in humans","volume":"11","author":"Zhang H","year":"2022","unstructured":"Zhang H, Jamieson KL, Grenier J, et al.. Myocardial iron deficiency and mitochondrial dysfunction in advanced heart failure in humans. J Am Heart Assoc. 2022, 11:e022853. 10.1161\/JAHA.121.022853","journal-title":"J Am Heart Assoc"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2454","article-title":"Cardiac energetics in patients with chronic heart failure and iron deficiency: an in-vivo\u200931 P magnetic resonance spectroscopy study","volume":"24","author":"Papalia F","year":"2022","unstructured":"Papalia F, Jouhra F, Amin-Youssef G, Shah AM, Charles-Edwards G, Okonko DO. Cardiac energetics in patients with chronic heart failure and iron deficiency: an in-vivo\u200931 P magnetic resonance spectroscopy study. Eur J Heart Fail. 2022, 24:716-23. 10.1002\/ejhf.2454","journal-title":"Eur J Heart Fail"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.13265","article-title":"Iron deficiency in heart failure","volume":"8","author":"Loncar G","year":"2021","unstructured":"Loncar G, Obradovic D, Thiele H, von Haehling S, Lainscak M. Iron deficiency in heart failure. ESC Heart Fail. 2021, 8:2368-79. 10.1002\/ehf2.13265","journal-title":"ESC Heart Fail"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski P","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, et al.. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016, 37:2129-200. 10.1093\/eurheartj\/ehw128","journal-title":"Eur Heart J"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199912233412607","article-title":"Disorders of iron metabolism","volume":"341","author":"Andrews NC","year":"1999","unstructured":"Andrews NC. Disorders of iron metabolism. N Engl J Med. 1999, 341:1986-95. 10.1056\/NEJM199912233412607","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.12485","article-title":"Retrospective analysis into differences in heart failure patients with and without iron deficiency or anaemia","volume":"6","author":"Jacob C","year":"2019","unstructured":"Jacob C, Altevers J, Barck I, Hardt T, Braun S, Greiner W. Retrospective analysis into differences in heart failure patients with and without iron deficiency or anaemia. ESC Heart Fail. 2019, 6:840-55. 10.1002\/ehf2.12485","journal-title":"ESC Heart Fail"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.161","article-title":"Iron deficiency in a multi-ethnic Asian population with and without heart failure: prevalence, clinical correlates, functional significance and prognosis","volume":"16","author":"Yeo TJ","year":"2014","unstructured":"Yeo TJ, Yeo PS, Ching-Chiew Wong R, et al.. Iron deficiency in a multi-ethnic Asian population with and without heart failure: prevalence, clinical correlates, functional significance and prognosis. Eur J Heart Fail. 2014, 16:1125-32. 10.1002\/ejhf.161","journal-title":"Eur J Heart Fail"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.513","article-title":"Iron deficiency and risk of early readmission following a hospitalization for acute heart failure","volume":"18","author":"N\u00fa\u00f1ez J","year":"2016","unstructured":"N\u00fa\u00f1ez J, Com\u00edn-Colet J, Mi\u00f1ana G, et al.. Iron deficiency and risk of early readmission following a hospitalization for acute heart failure. Eur J Heart Fail. 2016, 18:798-802. 10.1002\/ejhf.513","journal-title":"Eur J Heart Fail"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.837","article-title":"Iron status and inflammatory biomarkers in patients with acutely decompensated heart failure: early in-hospital phase and 30-day follow-up","volume":"19","author":"Van Aelst LN","year":"2017","unstructured":"Van Aelst LN, Abraham M, Sadoune M, et al.. Iron status and inflammatory biomarkers in patients with acutely decompensated heart failure: early in-hospital phase and 30-day follow-up. Eur J Heart Fail. 2017, 19:1075-6. 10.1002\/ejhf.837","journal-title":"Eur J Heart Fail"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.hlc.2015.06.827","article-title":"Iron deficiency in heart failure: looking beyond anaemia","volume":"25","author":"Wong CC","year":"2016","unstructured":"Wong CC, Ng AC, Kritharides L, Sindone AP. Iron deficiency in heart failure: looking beyond anaemia. Heart Lung Circ. 2016, 25:209-16. 10.1016\/j.hlc.2015.06.827","journal-title":"Heart Lung Circ"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1080\/00015385.2017.1351239","article-title":"Impact of iron deficiency on exercise capacity and outcome in heart failure with reduced, mid-range and preserved ejection fraction","volume":"73","author":"Martens P","year":"2018","unstructured":"Martens P, Nijst P, Verbrugge FH, Smeets K, Dupont M, Mullens W. Impact of iron deficiency on exercise capacity and outcome in heart failure with reduced, mid-range and preserved ejection fraction. Acta Cardiol. 2018, 73:115-23. 10.1080\/00015385.2017.1351239","journal-title":"Acta Cardiol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1186\/s43044-021-00200-6","article-title":"Anemia in heart failure: still an unsolved enigma","volume":"73","author":"Sharma YP","year":"2021","unstructured":"Sharma YP, Kaur N, Kasinadhuni G, Batta A, Chhabra P, Verma S, Panda P. Anemia in heart failure: still an unsolved enigma. Egypt Heart J. 2021, 73:75. 10.1186\/s43044-021-00200-6","journal-title":"Egypt Heart J"},{"key":"ref20","article-title":"[Intravenous iron-dextran: therapeutic and experimental possibilities]","volume":"100","author":"Ganzoni AM","year":"1970","unstructured":"Ganzoni AM. [Intravenous iron-dextran: therapeutic and experimental possibilities]. Schweiz Med Wochenschr. 1970, 100:301-3.","journal-title":"Schweiz Med Wochenschr"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32339-4","article-title":"Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial","volume":"396","author":"Ponikowski P","year":"2020","unstructured":"Ponikowski P, Kirwan BA, Anker SD, et al.. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet. 2020, 396:1895-904. 10.1016\/S0140-6736(20)32339-4","journal-title":"Lancet"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1177\/10742484211055639","article-title":"IV sodium ferric gluconate complex in patients hospitalized due to acute decompensated heart failure and iron deficiency","volume":"27","author":"Borreda I","year":"2022","unstructured":"Borreda I, Zukermann R, Epstein D, Marcusohn E. IV sodium ferric gluconate complex in patients hospitalized due to acute decompensated heart failure and iron deficiency. J Cardiovasc Pharmacol Ther. 2022, 27:10742484211055639. 10.1177\/10742484211055639","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908355","article-title":"Ferric carboxymaltose in patients with heart failure and iron deficiency","volume":"361","author":"Anker SD","year":"2009","unstructured":"Anker SD, Comin Colet J, Filippatos G, et al.. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009, 361:2436-48. 10.1056\/NEJMoa0908355","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu385","article-title":"Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency","volume":"36","author":"Ponikowski P","year":"2015","unstructured":"Ponikowski P, van Veldhuisen DJ, Comin-Colet J, et al.. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J. 2015, 36:657-68. 10.1093\/eurheartj\/ehu385","journal-title":"Eur Heart J"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.027497","article-title":"Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency","volume":"136","author":"van Veldhuisen DJ","year":"2017","unstructured":"van Veldhuisen DJ, Ponikowski P, van der Meer P, et al.. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation. 2017, 136:1374-83. 10.1161\/CIRCULATIONAHA.117.027497","journal-title":"Circulation"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.5427","article-title":"Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency: the IRONOUT HF randomized clinical trial","volume":"317","author":"Lewis GD","year":"2017","unstructured":"Lewis GD, Malhotra R, Hernandez AF, et al.. Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency: the IRONOUT HF randomized clinical trial. JAMA. 2017, 317:1958-66. 10.1001\/jama.2017.5427","journal-title":"JAMA"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2628","article-title":"Intravenous iron therapy improves the hypercapnic ventilatory response and sleep disordered breathing in chronic heart failure [In press]","author":"Caravita S","year":"2022","unstructured":"Caravita S, Faini A, Vignati C, et al.. Intravenous iron therapy improves the hypercapnic ventilatory response and sleep disordered breathing in chronic heart failure [In press]. Eur J Heart Fail. 2022, 10.1002\/ejhf.2628","journal-title":"Eur J Heart Fail"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.09.036","article-title":"Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial","volume":"51","author":"Okonko DO","year":"2008","unstructured":"Okonko DO, Grzeslo A, Witkowski T, et al.. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol. 2008, 51:103-12. 10.1016\/j.jacc.2007.09.036","journal-title":"J Am Coll Cardiol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2013.04.181","article-title":"IRON-HF study: a randomized trial to assess the effects of iron in heart failure patients with anemia","volume":"168","author":"Beck-da-Silva L","year":"2013","unstructured":"Beck-da-Silva L, Piardi D, Soder S, et al.. IRON-HF study: a randomized trial to assess the effects of iron in heart failure patients with anemia. Int J Cardiol. 2013, 168:3439-42. 10.1016\/j.ijcard.2013.04.181","journal-title":"Int J Cardiol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.12432","article-title":"Budget impact of intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency in France","volume":"6","author":"Bourguignon S","year":"2019","unstructured":"Bourguignon S, Faller M, Champs FO, Moutier H, Levesque K, Caranhac G, Cohen-Solal A. Budget impact of intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency in France. ESC Heart Fail. 2019, 6:559-69. 10.1002\/ehf2.12432","journal-title":"ESC Heart Fail"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.07.029","article-title":"Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency","volume":"50","author":"Toblli JE","year":"2007","unstructured":"Toblli JE, Lombra\u00f1a A, Duarte P, Di Gennaro F. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol. 2007, 50:1657-65. 10.1016\/j.jacc.2007.07.029","journal-title":"J Am Coll Cardiol"},{"key":"ref32","unstructured":"Effect of IV iron in patients with heart failure with preserved ejection fraction. (2020). Accessed. September 28, 2022: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03074591."},{"key":"ref33","unstructured":"Intravenous iron in patients with systolic heart failure and iron deficiency to improve morbidity & mortality. (2021). Accessed. September 28, 2022: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03036462."},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.120.008100","article-title":"Randomized placebo-controlled trial of ferric carboxymaltose in heart failure with iron deficiency: rationale and design","volume":"14","author":"Mentz RJ","year":"2021","unstructured":"Mentz RJ, Ambrosy AP, Ezekowitz JA, et al.. Randomized placebo-controlled trial of ferric carboxymaltose in heart failure with iron deficiency: rationale and design. Circ Heart Fail. 2021, 14:e008100. 10.1161\/CIRCHEARTFAILURE.120.008100","journal-title":"Circ Heart Fail"},{"key":"ref35","unstructured":"Differential gene expression in patients with heart failure and iron deficiency - effects of ferric carboxymaltose. (2018). Accessed. September 28, 2022: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01978028."},{"key":"ref36","unstructured":"Ferric carboxymaltose to improve skeletal muscle metabolism in heart failure patients with functional iron deficiency. (2022). Accessed. September 28, 2022: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03218384."},{"key":"ref37","unstructured":"Intravenous iron treatment in patients with heart failure and iron deficiency. IRONMAN. (2022). Accessed: September 28, 2022: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02642562."},{"key":"ref38","unstructured":"Short term oral iron supplementation in systolic heart failure patients suffering from iron deficiency anemia. (2016). Accessed. September 28, 2022: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02998697."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/118847-iron-deficiency-in-heart-failure-what-do-we-know-so-far","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:42:18Z","timestamp":1707507738000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/118847-iron-deficiency-in-heart-failure-what-do-we-know-so-far"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,16]]},"references-count":38,"URL":"https:\/\/doi.org\/10.7759\/cureus.30348","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,16]]}}}